CIPLA: CO. SIGNS EXCLUSIVE LICENSING AGREEMENT WITH SBP GROUP FOR HER2 BISPECIFIC ADC ROLDITAMIG DEUDERUXTECAN (TQB2102); AGREEMENT COVERS INDIA, SOUTH AFRICA, AND FIVE OTHER EMERGING MARKETS; CIPLA TO HANDLE LOCAL DEVELOPMENT AND COMMERCIALIZATION.
August 31, 2026 974
